CD200 as a Prognostic Factor in Acute Myeloid Leukemia
Marwa Mohamed El Kotb Mohamed;
Abstract
The prognostic impact of CD200 in hematological malignancies has gained significant attention over the past few years.Recent studies considered CD200 as a marker of bad prognosis in AML patients as it is linked to worse overall survival among them.
The aim of the present study was to measure CD200 expression in AML patients and to detect its relation with patients' outcome and standard prognostic factors. The study was carried on 40 newly diagnosed AML patientsattending the Hematology- Oncology Unit-Ain-Shams University Hospitals including:24 males (60%) and 16 females (40%) with age ranging from 18 to 75 years with a mean value of 42.05±15.6years and10 healthy subjects who served as a control group, including: 6 males (60%) and 4 females (40%) with age ranging from 17 to 53 years with a mean value of 36.9±11.1 years.
All patients were subjected to complete history taking, thorough clinical examination and laboratory investigations including: CBC, BM aspiration with examination of leishman-stained PB and BM smears, IPT, cytogenetic analysis and measurement of CD200level
CD200was measured in patients and control groups using anti CD200 mAb (PE) by EPICS XL Coulter.Regarding CD200 expression: 31(77.5%) of AML patients were positive while, none of the control group expressed CD200.
No difference was found regarding neither the studied demographic, clinical nor laboratory data betweenCD200 positive and CD200 negative patients' groups except for PB and BM blasts, they were higher in CD200 positive patients' group (P=0.03, P=0.04respectively). No difference was found regardingneither the studied FAB subclasses nor the IPT markers CD34,CD33,CD117,CD13 between CD200 positive and CD200 negative patients' groups, whilesignificant difference was found in HLA-DR and MPO expression, as they were higher in CD200 positive patients' group(P=0.043, P=0.028 respectively). Concerning the CD200expression and cytogenetic analysis, we found that the CD200 expression was higher among patients with unfavorable chromosomal aberrations poor outcome patients' group(P=0.024048). Also, we found that CD200 expression was higher among poor outcome patients' group (P = 0.024).
The aim of the present study was to measure CD200 expression in AML patients and to detect its relation with patients' outcome and standard prognostic factors. The study was carried on 40 newly diagnosed AML patientsattending the Hematology- Oncology Unit-Ain-Shams University Hospitals including:24 males (60%) and 16 females (40%) with age ranging from 18 to 75 years with a mean value of 42.05±15.6years and10 healthy subjects who served as a control group, including: 6 males (60%) and 4 females (40%) with age ranging from 17 to 53 years with a mean value of 36.9±11.1 years.
All patients were subjected to complete history taking, thorough clinical examination and laboratory investigations including: CBC, BM aspiration with examination of leishman-stained PB and BM smears, IPT, cytogenetic analysis and measurement of CD200level
CD200was measured in patients and control groups using anti CD200 mAb (PE) by EPICS XL Coulter.Regarding CD200 expression: 31(77.5%) of AML patients were positive while, none of the control group expressed CD200.
No difference was found regarding neither the studied demographic, clinical nor laboratory data betweenCD200 positive and CD200 negative patients' groups except for PB and BM blasts, they were higher in CD200 positive patients' group (P=0.03, P=0.04respectively). No difference was found regardingneither the studied FAB subclasses nor the IPT markers CD34,CD33,CD117,CD13 between CD200 positive and CD200 negative patients' groups, whilesignificant difference was found in HLA-DR and MPO expression, as they were higher in CD200 positive patients' group(P=0.043, P=0.028 respectively). Concerning the CD200expression and cytogenetic analysis, we found that the CD200 expression was higher among patients with unfavorable chromosomal aberrations poor outcome patients' group(P=0.024048). Also, we found that CD200 expression was higher among poor outcome patients' group (P = 0.024).
Other data
| Title | CD200 as a Prognostic Factor in Acute Myeloid Leukemia | Other Titles | السيدي 200 كمآلللمرض فيحالاتسرطانالدمالميلودىالحاد | Authors | Marwa Mohamed El Kotb Mohamed | Issue Date | 2014 |
Recommend this item
Similar Items from Core Recommender Database
Items in Ain Shams Scholar are protected by copyright, with all rights reserved, unless otherwise indicated.